Please assess the completion status of the following clinical trial:

Trial Title: Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ovarian or primary peritoneal cancer confirmed by pathology~* Patients must have recurrent ovarian cancer which is sensitive to platinum therapy~* Prior radiation therapy is allowed~Measurable disease as defined by the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines, or non-measurable but cancer antigen 125 (CA-125) greater than or equal to 2X upper limit.~Exclusion Criteria:~* More than 2 lines of therapy for ovarian or primary peritoneal cancer.~* Pregnant or breast feeding.~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed/Carboplatin Phase 1 (Type: EXPERIMENTAL): Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion.
- Pemetrexed/Carboplatin Phase 2 (Type: EXPERIMENTAL): Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).